Utilization of metabolomics to identify serum biomarkers for hepatocellular carcinoma in patients with liver cirrhosis

Habtom W. Ressom, Jun Feng Xiao, Leepika Tuli, Rency S. Varghese, Bin Zhou, Tsung Heng Tsai, Mohammad R. Nezami Ranjbar, Yi Zhao, Jinlian Wang, Cristina Di Poto, Amrita K. Cheema, Mahlet G. Tadesse, Radoslav Goldman, Kirti Shetty

Research output: Contribution to journalArticle

Abstract

Characterizing the metabolic changes pertaining to hepatocellular carcinoma (HCC) in patients with liver cirrhosis is believed to contribute towards early detection, treatment, and understanding of the molecular mechanisms of HCC. In this study, we compare metabolite levels in sera of 78 HCC cases with 184 cirrhotic controls by using ultra performance liquid chromatography coupled with a hybrid quadrupole time-of-flight mass spectrometry (UPLC-QTOF MS). Following data preprocessing, the most relevant ions in distinguishing HCC cases from patients with cirrhosis are selected by parametric and non-parametric statistical methods. Putative metabolite identifications for these ions are obtained through mass-based database search. Verification of the identities of selected metabolites is conducted by comparing their MS/MS fragmentation patterns and retention time with those from authentic compounds. Quantitation of these metabolites is performed in a subset of the serum samples (10 HCC and 10 cirrhosis) using isotope dilution by selected reaction monitoring (SRM) on triple quadrupole linear ion trap (QqQLIT) and triple quadrupole (QqQ) mass spectrometers. The results of this analysis confirm that metabolites involved in sphingolipid metabolism and phospholipid catabolism such as sphingosine-1-phosphate (S-1-P) and lysophosphatidylcholine (lysoPC 17:0) are up-regulated in sera of HCC vs. those with liver cirrhosis. Down-regulated metabolites include those involved in bile acid biosynthesis (specifically cholesterol metabolism) such as glycochenodeoxycholic acid 3-sulfate (3-sulfo-GCDCA), glycocholic acid (GCA), glycodeoxycholic acid (GDCA), taurocholic acid (TCA), and taurochenodeoxycholate (TCDCA). These results provide useful insights into HCC biomarker discovery utilizing metabolomics as an efficient and cost-effective platform. Our work shows that metabolomic profiling is a promising tool to identify candidate metabolic biomarkers for early detection of HCC cases in high risk population of cirrhotic patients.

Original languageEnglish (US)
Pages (from-to)90-100
Number of pages11
JournalAnalytica Chimica Acta
Volume743
DOIs
StatePublished - Sep 19 2012

Keywords

  • Biomarkers
  • Hepatocellular carcinoma
  • Liquid chromatography-mass spectrometry
  • Metabolomics
  • Selected reaction monitoring

ASJC Scopus subject areas

  • Analytical Chemistry
  • Biochemistry
  • Environmental Chemistry
  • Spectroscopy

Fingerprint Dive into the research topics of 'Utilization of metabolomics to identify serum biomarkers for hepatocellular carcinoma in patients with liver cirrhosis'. Together they form a unique fingerprint.

  • Cite this

    Ressom, H. W., Xiao, J. F., Tuli, L., Varghese, R. S., Zhou, B., Tsai, T. H., Nezami Ranjbar, M. R., Zhao, Y., Wang, J., Di Poto, C., Cheema, A. K., Tadesse, M. G., Goldman, R., & Shetty, K. (2012). Utilization of metabolomics to identify serum biomarkers for hepatocellular carcinoma in patients with liver cirrhosis. Analytica Chimica Acta, 743, 90-100. https://doi.org/10.1016/j.aca.2012.07.013